Top Markets
#1 Siren Siren +35.55%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.06%
#3 PulseChain PulseChain +17.72%
#4 Ribbita by Virtuals Ribbita by Virtuals +17.03%
#5 OpenEden OpenEden +16.58%
#6 Cysic Cysic +16.56%
#7 BasedHype BasedHype +15.88%
#8 The Grays Currency The Grays Currency +15.71%
#9 KUB Coin KUB Coin +15.65%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +15.50%
Coin of the day
Siren Siren
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
Rang in aandelen #30831
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Aandeelprijs
$0.343985
Marktkapitalisatie
$15.40M
Verandering (1 dag)
3.94%
Verandering (1 jaar)
-25.19%
Land
BE
Handel Celyad Oncology S.A. (CYAD)

Categorie

Healthcare
Omzet van Celyad Oncology S.A. (CYAD)
Omzet in Aug 2026 TTM: 0
Volgens de laatste financiële rapporten van Celyad Oncology S.A. bedraagt de huidige omzet van het bedrijf (TTM) 0. In 2026 behaalde het bedrijf een omzet van 0 gelijk aan de omzet in het jaar 2026, die 0 bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Celyad Oncology S.A. van 2026 tot 2026
Omzet aan het einde van elk jaar
Jaar Omzet Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Omzet van vergelijkbare bedrijven of concurrenten
Bedrijf Omzet Omzetverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE